Literature DB >> 28848820

Significance of Patent Foramen Ovale in Patients with GOLD Stage II Chronic Obstructive Pulmonary Disease (COPD).

Dario Martolini1,2, Rebecca Tanner1, Claire Davey1, Mehul S Patel1, Davide Elia1, Helen Purcell1, Paolo Palange2, Nicholas S Hopkinson1, Michael I Polkey1.   

Abstract

Background: Patent foramen ovale (PFO) is a common finding in adults. A PFO is associated with right to left shunting but its importance in the aetiology of hypoxia in early COPD remains uncertain, although it has not proved possible to demonstrate a role for PFOs in the aetiology of hypoxia in patients with Global Initiative for chronic Obstructive Lung Disease (GOLD) stage III/IV disease. We compared the characteristics of GOLD stage II patients with or without a PFO and assessed its impact on exercise performance.
Methods: In 22 GOLD stage II COPD patients we measured exercise performance, arterial oxygen tension and lung function and used contrast transcranial Doppler ultrasonography (TCD) to assess the presence of a PFO. Patients (n=20) underwent TCD measurements during incremental cycle ergometry with respiratory pressures measured using an esophageal balloon catheter (n=13).
Results: Twelve individuals (54%) had a PFO. Patients with a PFO were more hypoxic; mean(SD) partial pressure of oxygen in arterial blood (PaO2)10.2(1.1) kilopascals (kPa) vs. 11.7(0.9)kPa (p<0.01), but the presence of a PFO was not associated with reduced exercise performance either on cycle ergometry or a 6 Minute Walk Test (6MWT). A strong relationship was noted between the esophageal pressure swing (PSwingEs) and the degree of shunting observed during exercise (r=0.7; p<0.001). Conclusions:The presence of a PFO in GOLD stage II COPD patients does not appear to influence exercise performance despite increased right-to-left shunting.

Entities:  

Keywords:  arterial oxygenation; chronic obstructive pulmonary disease; exercise and lung function

Year:  2014        PMID: 28848820      PMCID: PMC5556863          DOI: 10.15326/jcopdf.1.2.2013.0003

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  24 in total

1.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung.

Authors:  N Macintyre; R O Crapo; G Viegi; D C Johnson; C P M van der Grinten; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; P Gustafsson; J Hankinson; R Jensen; R McKay; M R Miller; D Navajas; O F Pedersen; R Pellegrino; J Wanger
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

Review 2.  Arterial versus capillary blood gases: a meta-analysis.

Authors:  Gerald S Zavorsky; Jiguo Cao; Nancy E Mayo; Rina Gabbay; Juan M Murias
Journal:  Respir Physiol Neurobiol       Date:  2006-08-17       Impact factor: 1.931

3.  Diagnosis and quantification of patent foramen ovale. Which is the reference technique? Simultaneous study with transcranial Doppler, transthoracic and transesophageal echocardiography.

Authors:  Teresa González-Alujas; Artur Evangelista; Estevo Santamarina; Marta Rubiera; Zamira Gómez-Bosch; José F Rodríguez-Palomares; Gustavo Avegliano; Carlos Molina; José Alvarez-Sabín; David García-Dorado
Journal:  Rev Esp Cardiol       Date:  2011-02       Impact factor: 4.753

4.  Patent foramen ovale among patients with mild chronic obstructive pulmonary disease and unexplained hypoxia.

Authors:  Harun Kilic; Mustafa M Balci; Murat N Aksoy; Esra Bilgin; Kevser G Gülsoy; Ekrem Yeter; Sadik Acikel; Ramazan Akdemir
Journal:  Echocardiography       Date:  2010-03-25       Impact factor: 1.724

5.  Breathlessness and skeletal muscle weakness in patients undergoing lung health screening in primary care.

Authors:  Julia L Kelly; Sarah L Elkin; Jonathan Fluxman; Michael I Polkey; Michael A Soljak; Nicholas S Hopkinson
Journal:  COPD       Date:  2012-12-28       Impact factor: 2.409

6.  Transcranial Doppler and transesophageal echocardiography: comparison of both techniques and prospective clinical relevance of transcranial Doppler in patent foramen ovale detection.

Authors:  Luigi Caputi; Maria Rita Carriero; Chiara Falcone; Eugenio Parati; Patrizia Piotti; Carlo Materazzo; Gian Paolo Anzola
Journal:  J Stroke Cerebrovasc Dis       Date:  2009 Sep-Oct       Impact factor: 2.136

7.  Patent foramen ovale: comparison among diagnostic strategies in cryptogenic stroke and migraine.

Authors:  Concetta Zito; Giuseppe Dattilo; Giuseppe Oreto; Gianluca Di Bella; Annalisa Lamari; Raffaella Iudicello; Olimpia Trio; Giuseppe Caracciolo; Sebastiano Coglitore; Francesco Arrigo; Scipione Carerj
Journal:  Echocardiography       Date:  2009-05       Impact factor: 1.724

8.  Patent foramen ovale in severe obstructive sleep apnea: clinical features and effects of closure.

Authors:  Zarrin F Shaikh; Jay Jaye; Neil Ward; Atul Malhotra; Manuel de Villa; Michael I Polkey; Michael J Mullen; Mary J Morrell
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

9.  Patent foramen ovale is not associated with hypoxemia in severe chronic obstructive pulmonary disease and does not impair exercise performance.

Authors:  Zarrin F Shaikh; Julia L Kelly; Dinesh Shrikrishna; Manuel de Villa; Michael J Mullen; Nicholas S Hopkinson; Mary J Morrell; Michael I Polkey
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

10.  Lung function indices for predicting mortality in COPD.

Authors:  Afroditi K Boutou; Dinesh Shrikrishna; Rebecca J Tanner; Cayley Smith; Julia L Kelly; Simon P Ward; Michael I Polkey; Nicholas S Hopkinson
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

View more
  2 in total

1.  Unexplained hypoxemia in COPD with cardiac shunt.

Authors:  Rino Frizzelli; Corrado Lettieri; Simone Caiola; Linda Maulucci; Claudio Pinzi; Francesco Agostini; Annalisa Frizzelli
Journal:  Respir Med Case Rep       Date:  2022-05-05

Review 2.  Potential Role of Patent Foramen Ovale in Exacerbating Hypoxemia in Chronic Pulmonary Disease.

Authors:  Michael E Layoun; Jamil A Aboulhosn; Jonathan M Tobis
Journal:  Tex Heart Inst J       Date:  2017-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.